Pamapimod

DB19169InvestigationalSmall molecule

Pamapimod is under investigation in clinical trial NCT05659459 (The KIN-FAST Trial (KIN001 for Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With Sars-cov-2).

Mechanism: Pharmacologically active on Mitogen-activated protein kinase 14
Curator reviewed
Formula / weight: C₁₉H₂₀F₂N₄O₄ · 406.39 g/mol (avg)
Also known as: 6-(2,4-Difluorophenoxy)-2-{[3-hydroxy-1-(2-hydroxyethyl)propyl]amino}-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
Code names: R-1503 · RO-4402257

Resolves to

Compound

UNII8S2C9V11K4CAS449811-01-2ChEMBLCHEMBL1090089ChEBI90685

Structure

InChIKeyJYYLVUFNAHSSFE-UHFFFAOYSA-NSMILESCN1C(=O)C(OC2=CC=C(F)C=C2F)=CC2=CN=C(NC(CCO)CCO)N=C12

Targets

Q16539MAPK14

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pamapimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account